Facts and Hopes in Cancer Antigens Recognized by T Cells.
(2023) Clinical cancer research — Vol. 29, n° 2, p. 309-315 (2023)
Files
2023_Brochier_Clin_Cancer_Res.pdf
Open Access - Adobe PDF
- 1.58 MB
Details
- Authors
Brochier, Walther 
Bricard, Orian
- Abstract
- T cells are key effectors of our immune response against tumors and exert their antitumor effects upon recognizing a variety of tumor-specific peptides presented by HLA molecules on the surface of tumor cells. The identification of the tumor-specific antigens of a given tumor is not required for immune checkpoint therapy (ICT), which mainly reactivates existing tumor-specific T cells together with T cells of unknown specificities. To decrease the activation of non-tumor-specific T cells, active or passive immunizations against tumor-specific antigens are considered. These immunizations require the identification of at least some of the tumor-specific antigens displayed on the tumor cells of a patient. While this has become an easy task for tumors with a large number of mutations generating neoantigens, it remains difficult for the remainder. Here, we review some facts about human tumor-specific or tumor-associated antigens, as well as some hopes for their future use in cancer immunotherapy.
- Affiliations
Citations
Brochier, W., Bricard, O., & Coulie, P. (2023). Facts and Hopes in Cancer Antigens Recognized by T Cells. Clinical cancer research, 29(2), 309-315. https://doi.org/10.1158/1078-0432.CCR-21-3798 (Original work published 2023)